Literature DB >> 10594397

Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.

D A Revicki1, J A Crawley, M W Zodet, D S Levine, B O Joelsson.   

Abstract

BACKGROUND: Medical treatments for gastro-oesophageal reflux disease (GERD) vary in their ability to completely resolve heartburn and other symptoms. Although GERD reduces health-related quality of life (HRQL) little is known about the relationship between resolution of heartburn symptoms with medical therapy and HRQL. We evaluated the association between complete resolution of heartburn symptoms and functioning and well-being in three samples of patients with GERD.
METHODS: We analysed baseline and follow-up assessments of heartburn symptoms and HRQL scores from three clinical trials (total n=1351) comparing omeprazole and ranitidine for acute symptomatic treatment of GERD. Heartburn symptoms were measured using patient diaries and/or patient self-report. HRQL was assessed using the Psychological General Well-Being Index (PGWB) in all three clinical trials and the SF-36 Health Survey in two clinical trials. Resolution of heartburn symptoms was defined as no heartburn reported during the assessment period.
RESULTS: We observed statistically significant differences favouring patients with no heartburn symptoms on the PGWB total score (P=0.018 to P < 0.0001) and anxiety (P=0.002 to P < 0.0001), general health (P=0.05 to P < 0. 0001), positive well-being (P=0.028 to P < 0.0001) and vitality (P=0. 05 to P < 0.0001) sub-scale scores at 4-14 weeks. Patients with no heartburn reported better SF-36 pain (P=0.005 to P < 0.0001) and general health perceptions (P=0.032 to P < 0.0001) compared with patients still experiencing heartburn symptoms at 4-24 weeks. SF-36 physical component summary scores were significantly better in patients with no heartburn symptoms compared with patients with heartburn symptoms at 4-24 weeks (P=0.013 to P=0.009), while mental component summary scores were only significantly different at 24 weeks (P=0.0005) in one of the two studies where the SF-36 was utilized.
CONCLUSIONS: Complete resolution of heartburn symptoms was consistently associated with improvement in HRQL; the greatest impact was observed on measures of psychological well-being and physical functioning and well-being. Effective treatment of GERD that completely resolves heartburn results in clinically significant improvement in patient HRQL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594397     DOI: 10.1046/j.1365-2036.1999.00669.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

Review 1.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 2.  The impact of gastroesophageal reflux disease on quality of life.

Authors:  T Kamolz; R Pointner; V Velanovich
Journal:  Surg Endosc       Date:  2003-06-13       Impact factor: 4.584

3.  Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor?

Authors:  Anna Tavakkoli; Bisma A Sayed; Nicholas J Talley; Baharak Moshiree
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

4.  Development of a frequent heartburn index.

Authors:  Donald E Stull; Patricia van Hanswijck de Jonge; Katherine Houghton; Christopher Kocun; David W Sandor
Journal:  Qual Life Res       Date:  2011-01-12       Impact factor: 4.147

5.  Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX.

Authors:  Guy-Bernard Cadière; Nathalie Van Sante; Jaime E Graves; Anna K Gawlicka; Amin Rajan
Journal:  Surg Endosc       Date:  2009-03-14       Impact factor: 4.584

6.  Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.

Authors:  Robert J Hoogendoorn; Lex Groeneveld; J Andy Kwee
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).

Authors:  Anne Damiano; Kathleen Handley; Ellen Adler; Reshmi Siddique; Ashoke Bhattacharyja
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 8.  The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.

Authors:  Manishi Prasad; Anne M Rentz; Dennis A Revicki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study.

Authors:  Thirumazhisai Gunasekaran; Vasundhara Tolia; Richard B Colletti; Benjamin D Gold; Barry Traxler; Marta Illueca; Joseph A Crawley
Journal:  BMC Gastroenterol       Date:  2009-11-18       Impact factor: 3.067

10.  Impact of PPIs on patient focused symptomatology in GERD.

Authors:  Abr Thomson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.